Q-omics provides the consensus-scored DHX38 profile across patient tissues and cancer cell-line models. DHX38 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, DHX38 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, DHX38 protein abundance shows 31,881 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BLCA, HNSC, and LSCC as cancer lineages where DHX38 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DHX38 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DHX38 survival associations across molecular data types. DHX38 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DHX38 RNA expression–survival associations across cancer types. High DHX38 expression shows unfavorable associations in BLCA, ACC, LIHC and LUSC, but favorable associations in KIRC and SCLC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for DHX38 RNA expression.
This table summarizes DHX38 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 11. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DHX38. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DHX38 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, KIRP, LIHC and COAD. The HNSC box plot shows higher DHX38 RNA expression in tumor versus normal tissue (log2 FC = +0.766, t-test p < 0.001).
This table shows molecular features associated with DHX38 in patient tissues and cancer cell lines. In patient samples, DHX38 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, DHX38 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
